The effect of a Dried Bonito Broth on the hand-foot syndrome induced by targeted molecular therapy

The effect of Dried Bonito Broth on the hand-foot syndrome induced by targeted molecular therapy for hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180160

Enrollment

Registered

2019-02-26

Start date

2019-04-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hand Foot Syndrome Hand Foot Syndrome

Interventions

Uptake of a dried bonito broth

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients planned to be hospitalized for administration of sorafenib or regorafenib or lenvatinib molecular therapy for HCC. 2. Patients equal or over 20 years old.

Exclusion criteria

Exclusion criteria: 1. Patients who has food allergy to fish. 2. Patients who cannot eat and drink by themselves. 3. Patients who have a history of hand foot syndrome, skin disease, neurological disieases. 4. Patients for whom the physicians decided to be inappropriate candidate.

Design outcomes

Primary

Measure	Time frame
Occurrence of Hand-foot syndrome	—

Secondary

Measure	Time frame
Blood flow in the hands and feet; change of appetite and fatigue	—

Contacts

Public ContactKENYA KAMIMURA

Division of Gastroenterology and Hepatology, Niigata University

kenya-k@med.niigata-u.ac.jp+81-25-227-2207

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026